The IVI Foundation provides a platform for promotion, meeting, analysis and interdisciplinary debate for the medical and scientific communities in the field of reproductive medicine. The objective is to initiate, promote and coordinate fields of research that allow progress in the knowledge of human reproduction, improving the results of assisted reproduction treatments and reducing their adverse effects with the ultimate goal of combating infertility and improving results for those affected by infertility. The IVI Foundation was established in 1997 based on this philosophy and since then it has expanded its field of work to develop three fundamental pillars that provide the backbone of the Foundation today: Thereby allowing their development and evolution for the benefit of our patients, as well as creating general awareness within society to make this information available to people who may be beneficiaries of these treatments. LSHTM faculty regularly join an esteemed group of lecturers for the annual International Vaccinology Course, IVI’s flagship training program.Today, advances in any area of medicine and especially in Reproductive Medicine, require basic research to know the cause of the disease, or in this case the causes of reproductive failure to sustain the development of new diagnostic or therapeutic techniques. IVI and LSHTM share a commitment to facilitating the transfer of knowledge, know-how and technology to build capacity and collaborative networks, particularly in low-resource settings. Professor Beate Kampmann, Co-Director of the Vaccine Centre at LSHTM, said: “The Vaccine Centre at LSHTM is delighted to partner with IVI to strengthen our mutual vision of enhancing our understanding of the societal value of vaccines in all regions of the world through interdisciplinary research, training of the next generation of vaccinologists and advocacy.”
This includes basic science, preclinical studies and clinical trials, effectiveness and implementation studies, epidemiology, modelling, and economic evaluation to generate evidence for policy and facilitate introduction, uptake, and sustainable impact on vaccine equity.” We look forward to strengthening our collaborations across every stage of vaccine evaluation. We have ongoing research collaborations on impact assessment of licensed vaccines against typhoid fever, and new vaccines in the pipeline for Strep A, invasive non-typhoidal Salmonella, and chikungunya. Professor Dame Anne Mills, Deputy Director and Provost at LSHTM, said: “LSHTM and IVI have long-standing collaborations on research, education, and capacity-building. LSHTM alumni represent a number of IVI epidemiologists, clinicians, and biostatisticians, and we look forward to combining our multidisciplinary expertise to double our impact in improving global health through vaccination and capacity-building.”
Jerome Kim, Director General of IVI, said: “IVI is pleased to partner with LSHTM, a world-leading center for research and advanced education in public health, to train the next generation of vaccine scientists and advance critical vaccines through every stage of development. Joint activities will include developing materials to train early-career vaccinologists as well as collaborating across the entire spectrum of vaccine development.ĭr. The International Vaccine Institute (IVI), an international organisation with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and the London School of Hygiene & Tropical Medicine (LSHTM) signed a Memorandum of Understanding on September 30 to establish a collaborative partnership.
0 kommentar(er)
